News & Updates
Filter by Specialty:
Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis
Fedratinib is superior to the best available therapy (BAT) in terms of spleen volume reduction (SVR) and symptom response rates in patients with myelofibrosis (MF) treated with the Janus kinase inhibitor (JAKi) ruxolitinib, as shown in a study presented at ASH 2023.
Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis
24 Dec 2023
Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible
In the treatment of individuals with fibromyalgia, low-dose naltrexone does not appear to help reduce pain but might improve memory instead, as reported in a study.
Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible
22 Dec 2023
First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma
First-line combination immuno-oncology therapy (IO) with ipilimumab and nivolumab provides beneficial effects and has an acceptable safety profile in patients with metastatic renal cell carcinoma, as shown in a Japan study presented at ESMO Asia 2023.
First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma
22 Dec 2023
Faecal microbiota spores deliver benefit in older patients with C. diff recurrence
In an integrated analysis of two phase III ECOSPOR trials presented at AIBD 2023, faecal microbiota spores (ie, live-brpk) demonstrated favourable safety and efficacy signals for the treatment of recurrent Clostridioides (C.) difficile infection (CDI) in older individuals.
Faecal microbiota spores deliver benefit in older patients with C. diff recurrence
22 Dec 2023
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.